G
Gerold Meinhardt
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 65
Citations - 7918
Gerold Meinhardt is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Sorafenib & Hepatocellular carcinoma. The author has an hindex of 21, co-authored 61 publications receiving 5771 citations. Previous affiliations of Gerold Meinhardt include Bayer Corporation & Schering AG.
Papers
More filters
Journal ArticleDOI
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
Journal ArticleDOI
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie Tung-Ping Poon,Kwang Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabricio Souza,Marie Aude Le Berre,Gerold Meinhardt,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: The data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
Journal ArticleDOI
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Riccardo Lencioni,Josep M. Llovet,Guohong Han,Won Young Tak,Jiamei Yang,Alfredo Guglielmi,Seung Woon Paik,Maria Reig,Do Young Kim,Gar Yang Chau,Angelo Luca,Luis Ruiz del Arbol,Marie Aude Leberre,Woody Niu,Kate Nicholson,Gerold Meinhardt,Jordi Bruix +16 more
TL;DR: Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB -TACE alone.
Journal ArticleDOI
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
TL;DR: The angiogenesis biomarkers Ang2 and VEGF were independent predictors of survival in patients with advanced HCC, and none of the biomarkers tested significantly predicted response to sorafenib.
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi,William Jacot,Toshinari Yamashita,Joohyuk Sohn,Maria Vidal,Eriko Tokunaga,Junji Tsurutani,Naoto Ueno,Aleix Prat,Yee Soo Chae,Keun Seok Lee,Naoki Niikura,Yeon Hee Park,Bing Xue,Xiao-juan Wang,Miguel Gil-Gil,Wei Liu,Jean-Yves Pierga,Seock-Ah Im,Halle C. F. Moore,Hope S. Rugo,Rinat Yerushalmi,Flora Zagouri,Andrea Gombos,Sung-Bae Kim,Qiang Liu,Ting Luo,Cristina Saura,Peter Schmid,Tao Sun,Dhiraj Gambhire,Lotus Yung,Yibin Wang,Jasmeet Singh,Patrik Vitazka,Gerold Meinhardt,Nadia Harbeck,David Cameron +37 more
TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.